Real-life data on the efficacy and safety of ombitasvir/paritaprevir/ritonavir + dasabuvir +ribavirin in the patients with genotype 1 chronic hepatitis C virus infection in Serbia

Real-life data on the efficacy and safety of ombitasvir/paritaprevir/ritonavir + dasabuvir +ribavirin in the patients with genotype 1 chronic hepatitis C virus infection in Serbia

Background/Aim. The era of direct-acting antiviral (DAA) regimen in the treatment of chronic hepatitis C virus (HCV) started in 2011. The aim of this study was to assess the antiviral efficacy and safety of DAA regimen, ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) + dasabuvir (DSV) + ribavirin...

Full description

Bibliographic Details
Main Authors: Simonović-Babić Jasmina, Bojović Ksenija, Fabri Milotka, Cvejić Tatjana, Svorcan Petar, Nožić Darko, Jovanović Maja, Škrbić Ranko, Stojiljković Miloš P., Mijailović Željko
Format: Article
Language:English
Published: Military Health Department, Ministry of Defance, Serbia 2019-01-01
Series:Vojnosanitetski Pregled
Subjects:
antiviral agents
drug therapy, combination
hepatitis c, chronic
ritonavir
sulfonamides
Online Access:http://www.doiserbia.nb.rs/img/doi/0042-8450/2019/0042-84501700186S.pdf

Internet

http://www.doiserbia.nb.rs/img/doi/0042-8450/2019/0042-84501700186S.pdf

Similar Items